Patients with persisting neuro-ophthalmologic symptoms, or tumor size increase/reincrease during treatment, or PRL reincrease despite carrying on treatment (‘escape phenomenon’) should be referred to neurosurgery (see below at 5.c). This evidence concerns the gene PRL and neoplasm.